Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘European Association of Urology’

Arc de Triomphe, Paris

Scenes from EAU - Arc de Triomphe

Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC).

For example:

  1. How should abiraterone and MDV3100 be sequenced pre or post chemotherapy?
  2. Would combining the two drugs post chemo be a better strategy that leads to superior outcomes?
  3. Where does chemotherapy fit into this emerging paradigm?  Do we need chemotherapy in an new era of oral therapies?  If yes, which patients should be considered eligible?

Sights of 2012 EAU Congress

Greetings from the European Association of Urology (EAU) congress in Paris. Despite the grey drizzle typical of Europe in winter, this is actually quite an interesting meeting with lots of poster presentations.

One poster that caught my eye yesterday was from Martin Gleave’s group on clusterin knockdown synergising MDV3100 activity. Previously, we discussed on this blog how inhibiting clusterin with custirsen (OGX-011) potentiated docetaxel. At the AUA meeting last year, the issue of whether the same would happen with MDV3100 was suggested, as you can see in the short video blog.


This weekend I’m at the annual meeting of the European Association of Urology (EAU), which takes place here in Vienna, Austria.  It promises to be an interesting meeting, with new developments in the areas of bladder/urothelial, prostate and renal cancers being discussed.

For those of you interested in following remotely, here are the links to the scientific programme and the podcasts.  You can also browse the abstracts online.

According to the EAU:

“For the 2011 edition, more than 3,700 abstracts were submitted and reviewed by the EAU Scientific Congress Office. As a result, 1,111 abstracts and 50 video abstracts were accepted, and will be presented at 92 poster sessions and 8 video sessions.”

error: Content is protected !!